Thomas O’Connor is chemical engineer, science staff at the Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA.
Regulatory Considerations for Controlled Correspondence Related to Generic Drug Chemistry
An analysis of controlled correspondence between generic-drug manufacturers and FDA reveals patterns in questions about specific drug chemistry topics and the response to information provided in FDA guidance documents.
Flowsheet Models Modernize Pharmaceutical Manufacturing Design and Risk Assessment
In-silico design facilitates process optimization and evaluation of process control strategies.